Table 1. Summary of patient characteristics.
| Patient characteristics | Category | Count (Total: n = 211) | % |
|---|---|---|---|
| Sex | Female | 77 | 36.5 |
| Male | 134 | 63.5 | |
| Age median [years] (range) | 69 (43-87) | ||
| BMI median [kg/m2] (range) | 25.0 (14.2-48.8) | ||
| Smoking status | never | 75 | 35.5 |
| former | 103 | 48.8 | |
| present | 26 | 12.3 | |
| unknown | 7 | 3.3 | |
| Tumor | lung ca | 122 | 57.8 |
| colon ca (KRAS WT) | 35 | 16.6 | |
| head and neck ca | 8 | 3.8 | |
| pancreatic ca | 46 | 21.8 | |
| EGFRI applied | erlotinib1 | 133 | 63.0 |
| (100 mg) | (45) | ||
| (150 mg) | (84) | ||
| gefitinib | 11 | 5.2 | |
| cetuximab | 61 | 28.9 | |
| panitumumab | 6 | 2.8 | |
| Maximal skin rash during observation period (grades after NCI-CTCAE) | 0 | 45 | 21.3 |
| 1 | 80 | 37.9 | |
| 2 | 75 | 35.5 | |
| 3 | 11 | 5.2 |
1 Indicated standard erlotinib dose depends on tumor type.
Abbreviations: BMI, body mass index; ca, cancer; EGFRI, epidermal growth factor receptor inhibitor; NCI-CTCAE, National Cancer Institute - Common Terminology Criteria for Adverse Events; WT, wild type.